332369-75-2Relevant academic research and scientific papers
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
-
, (2008/06/13)
The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.
Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site
Kristiansen, Marit,Andersen, Birgitte,Iversen, Lars Fogh,Westergaard, Niels
, p. 3537 - 3545 (2007/10/03)
Inhibition of glycogen phosphorylase (GP) has attracted considerable attention during the last five to 10 years as a means of treating the elevated hepatic glucose production seen in patients with type 2 diabetes. Several different GP inhibitors binding t
Aromatic compounds
-
, (2008/06/13)
Disclosed are compounds of formula I wherein A, R1, R2, R3, R4and R5are described in the specification, pharmaceutical formulations comprising these compounds, the use of these compounds are medicaments, the use of these medicaments in the treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (NIDDM or Type 2 diabetes), as well as methods for treating diabetes comprising administration of these compounds.
